Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 |
---|---|---|---|---|---|
Gross Sales | 296.02 | 263.07 | 286.96 | 272.21 | 244.13 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 296.02 | 263.07 | 286.96 | 272.21 | 244.13 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 42.69 | 13.96 | 22.01 | 39.82 | 76.15 |
Total Income | 338.71 | 277.03 | 308.97 | 312.03 | 320.28 |
Total Expenditure | 314.94 | 270.06 | 293.15 | 286.08 | 258.44 |
PBIDT | 23.77 | 6.97 | 15.82 | 25.95 | 61.84 |
Interest | 2.03 | 1.85 | 1.67 | 1.91 | 2.01 |
PBDT | 21.74 | 5.12 | 14.15 | 24.04 | 59.83 |
Depreciation | 17.4 | 17.41 | 17.92 | 18.79 | 19.18 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0.01 | 0 | 0.69 | 0 | 2.56 |
Deferred Tax | 1.88 | -1.12 | -0.27 | 2.56 | 31.4 |
Reported Profit After Tax | 2.45 | -11.17 | -4.19 | 2.69 | 6.69 |
Minority Interest After NP | -0.35 | 0 | -0.33 | 0 | 0 |
Net Profit after Minority Interest | 2.8 | -11.17 | -3.86 | 2.69 | 6.69 |
Extra-ordinary Items | 30.48 | 5.51 | 5.52 | 27.95 | 47.15 |
Adjusted Profit After Extra-ordinary item | -27.68 | -16.68 | -9.38 | -25.26 | -40.46 |
EPS (Unit Curr.) | 0.46 | -1.8 | 0 | 0.44 | 1.09 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 8.02 | 2.64 | 5.51 | 9.53 | 25.33 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 0.82 | -4.24 | -1.46 | 0.98 | 2.74 |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.